Elraglusib Shows Encouraging Efficacy in Advanced Salivary Gland Cancer Treatment, Driving Actuate Therapeutics Stock Gains

Actuate Therapeutics, Inc. (ACTU) unveiled significant clinical breakthrough findings on Monday from its Phase II investigation into elraglusib as a combination therapy alongside carboplatin or cisplatin for managing advanced metastatic salivary gland malignancies. The trial encompassed both adenoid cystic carcinoma (ACC), representing 47% of participants, and non-ACC subtypes accounting for 53% of the study population.

The survival metrics revealed noteworthy outcomes across patient cohorts. Overall survival reached a median of 18.6 months across the full study population, with 58% of patients remaining alive at the one-year mark and 40% surviving through two years. Notably, non-ACC patients demonstrated superior median overall survival of 27.8 months compared to their ACC counterparts. In terms of disease progression, the median progression-free survival measured 6.4 months, though a meaningful subset of 27% achieved progression-free status at twelve months—a distinction particularly relevant when considering historical ACC progression-free survival estimates of 49 months and non-ACC benchmarks hovering below six months.

These clinical achievements, which found publication in the peer-reviewed journal Clinical Cancer Research, resonated positively with market participants. ACTU shares experienced an uptick exceeding 4% during pre-market trading sessions, building upon Friday’s close of $7.52 per share, which itself reflected a 1.35% daily gain. The results underscore the therapeutic potential of this combination approach in addressing previously challenging malignancies in the salivary gland cancer space.